Giant Global Study on 99 Million Vaccinated People Reveals Increases in Neurological, Blood, Heart Conditions Associated with COVID-19 Jabs

(TJV) According to a report from Fortune magazine, the largest study to date on recipients of COVID-19 vaccines concludes that while the vaccines effectively prevent severe illness, death, and long-term COVID symptoms, they are also associated with  increases in neurological, blood, and heart-related conditions.

You can read the full study here.

Conducted by the Global Vaccine Data Network, the study was recently published in the journal Vaccine, with detailed data accessible through interactive dashboards showcasing methodology and specific findings.

Examining 99 million individuals across eight countries who received COVID-19 vaccines, the study focused on 13 medical conditions deemed “adverse events of special interest” to pinpoint any elevated occurrences following vaccination.

Results indicated a heightened risk of heart-related inflammation associated with mRNA vaccines produced by Pfizer Inc., BioNTech SE, and Moderna Inc. Additionally, viral-vector vaccines, such as the one developed by the University of Oxford and manufactured by AstraZeneca Plc, were linked to an increased risk of specific adverse events, including a type of blood clot in the brain and Guillain-Barre syndrome, a neurological disorder.

Despite the administration of over 13.5 billion doses globally, which has saved over 1 million lives in Europe alone over the past three years, a small fraction of vaccine recipients experienced adverse effects, prompting ongoing discussion regarding the balance of benefits versus risks.

Notably, instances of myocarditis, or inflammation of the heart muscle, were consistently observed following mRNA vaccinations, with the Moderna vaccine showing the highest increase in risk after the second dose. Similarly, certain adverse events were associated with viral-vector vaccines, including an increased risk of cerebral venous sinus thrombosis and acute disseminated encephalomyelitis.

The study also highlighted potential safety signals for conditions like transverse myelitis and acute disseminated encephalomyelitis, although postural orthostatic tachycardia syndrome (POTS) was not specifically monitored.

The selection of adverse events of special interest was based on established associations with immunization, existing knowledge of immune-related conditions, and preclinical research. However, the study did not examine POTS, despite some prior research linking it with COVID-19 vaccines.

Gateway Pundit supploied a quick summary

Neurological Conditions:

• After getting the first dose of the Oxford/AstraZeneca vaccine, there was a noticeable increase in Guillain-Barré syndrome (GBS), where the body’s immune system attacks its nerves.
• Acute disseminated encephalomyelitis (ADEM), a rare brain and spinal cord inflammation, also popped up more than expected after the first Moderna vaccine dose.
• Other neurological issues like transverse myelitis (spinal cord inflammation), Bell’s palsy (facial paralysis), and seizures also occurred more than usual after some doses of these vaccines.

Blood Clot and Platelet Conditions:

• The Oxford/AstraZeneca vaccine first dose was linked to more cases of cerebral venous sinus thrombosis (CVST), a type of blood clot in the brain, than expected.
• There were also more instances of low platelet counts and pulmonary embolism (blood clots in the lungs) after some doses of Oxford/AstraZeneca, Pfizer, and Moderna vaccines.
• Some vaccines also led to an increase in splanchnic vein thrombosis (SVT), another type of blood clot, after certain doses, but these findings didn’t signal a major safety concern according to the study’s criteria.

Heart Conditions:

• Cases of myocarditis (heart inflammation) were significantly higher than expected after the first, second, and third doses of mRNA vaccines (like Pfizer and Moderna).
• Pericarditis (inflammation of the heart’s outer layer) cases also exceeded expectations after some doses of the Moderna vaccine and after the third dose of the Oxford/AstraZeneca vaccine.
• These heart-related findings were considered important safety signals that need attention.